On March 5, 2025, New Horizon Longevity successfully launched trading on the MINAX Global Brand Exchange and held a grand listing ceremony in Dubai, becoming the world’s first brand to promote the industrialization of traditional Chinese medicine through the RWA model. This initiative not only marks an important milestone for traditional Chinese medicine’s entry into the international capital market but also provides new ideas for the globalization and digitalization development of traditional Chinese medicine.

It is reported that New Horizon Longevity chose to list in Dubai this time, relying on the compliance system of the Minax Global Brand Exchange and taking advantage of the financial innovation environment in the United Arab Emirates to achieve the global circulation of brand assets.
“New Horizon Longevity’s choice of MINAX is a landmark layout for its brand digitization strategy,” said Wang Ping, CEO of New Horizon Longevity, at the ceremony. “By transforming intellectual property rights in the biotechnology field into tradable digital assets, we can not only reach a wider range of global investors but also convey the technical foundation and market potential of Chinese health brands to the world in a transparent and trustworthy manner.”

In recent years, the Chinese government has vigorously promoted the modernization and internationalization of traditional Chinese medicine. In 2022, the total number of consultations in traditional Chinese medicine health institutions across the country reached 1.23 billion, accounting for 14.6% of the total number of consultations nationwide. In 2023, the market scale of the traditional Chinese medicine industry was close to 800 billion yuan, with a growth rate ranking among the top in the pharmaceutical industry. Against this backdrop, the RWA listing of New Horizon Longevity will help enhance the influence of traditional Chinese medicine in the international market.

The introduction of RWA technology has enabled the traditional Chinese medicine industry to achieve the digitalization and financialization of assets. In the future, New Horizon Longevity will ensure the transparency of core assets such as brand value, traceability of medicinal materials, and patented technologies through blockchain technology, improve market trust, and provide global investors with a new way to participate in the traditional Chinese medicine industry.

Mr. Deng Di, the initiator of MINAX and the first advocate of brand RWA, pointed out that the brand RWA model of New Horizon Longevity is expected to become a digital benchmark in the traditional Chinese medicine industry and promote the capitalization process of the traditional Chinese medicine industry cluster in the international market. At the same time, due to Dubai’s unique geographical advantages and the environment of the integration of multiple cultures, it may become a trading hub for traditional Chinese medicine brand RWA in the future, helping traditional Chinese medicine take root globally.

With the accelerated digitalization and intelligence of the traditional Chinese medicine industry, the successful listing of the Novohope Longevity brand will further promote the globalization of the traditional Chinese medicine industry and provide more possibilities for Chinese traditional Chinese medicine to go global.

The MINAX Global Brand Exchange was jointly initiated and established by the MINAX GROUP Global Brand Trading Group and KLICKL, the first full-licensed digital asset institution in MENA (Middle East and North Africa). It has the compliance ability and license support for digital asset issuance in the United Arab Emirates.

MINAX will work together with professional investment banking institutions, investment funds, law firms, and audit firms to create a good ecological environment for brands to enter the Web3 field. MINAX will also provide convenience for small and medium-sized enterprises and even individuals to create and develop their own brands. Through various forms such as brand private placement, brand crowdfunding, and IBO, it will help brands obtain the first financing, the first group of fans, and the first batch of orders. At the same time, due to the global characteristics of Web3, brand assets can be traded 24 hours a day, 7 days a week on various global exchanges, and brand asset investors can come from all corners of the world. Investing in brands has never been so convenient.

As the world’s first brand asset exchange, MINAX has been committed to promoting the RWA process of brands and has made breakthrough progress in multiple markets such as Hong Kong, Macau, and Dubai. MINAX’s brand digital asset solution is becoming an important bridge connecting traditional brands and the Web3 world.

As the first eye health technology enterprise to list on the MINAX Global Brand Exchange, Novohope Longevity has successfully achieved the strategic upgrade of brand digitization through strategic cooperation with MINAX, accelerated its market expansion through its global platform, and further consolidated its international influence in the field of eye health technology.

Novohope Longevity has made remarkable achievements in the field of eye health. With its deep accumulation in scientific research and clinical practice, it has occupied a high ground in the industry and carried out technological innovation around the entire diagnosis and treatment chain, committed to bringing comprehensive and efficient solutions to eye disease patients.

The drug pipeline of Novohope Longevity has significant global innovation. The pipeline of the Herb-based Mingmu Presbyopia Eye Protection Solution 2.0 in its breakthrough drug R&D pipeline is expected to benefit patients with diabetic retinopathy, presbyopia, age-related macular degeneration, cataract, and glaucoma. In addition, the company actively conducts external cooperation. It has joined hands with Professor Zhou from the Hong Kong Polytechnic University and the Hong Kong government to develop eye drops and oral supplements for the treatment of diabetic retinopathy and presbyopia. It has also collaborated with Dean Feng of the School of Chinese Medicine at the University of Hong Kong and the Hong Kong government to advance the research and development of the drug pipeline for diabetic retinopathy and the pipeline for macular degeneration.

With its scientific research strength, rich products, and innovative drug R&D pipeline in the field of eye health, Novohope Longevity is gradually becoming a leading enterprise in the eye health industry and will continue to bring more hope to eye disease patients around the world in the future.